Barcelona Liver Bioservices announces collaboration with GAT Therapeutics

23 March, 2020

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with GAT Therapeutics, an early stage biopharma targeting fibrosis and age-related diseases.

 

Under the terms of the agreement, BLB will deeply characterize the effects of GATTx’s lead compound GTX-011 on non-alcoholic steatohepatitis (NASH), liver cirrhosis and portal hypertension. The research plan incorporates different BLB’s proprietary methods & technology, including the BarNa model®, unique pre-clinical model of NASH that mimics key pathophysiological and transcriptomic features of the human disease, and the exclusive ExoLiver® platform, BLB’s advanced model of human liver disease.

 

BLB aims at providing valuable insights into complex disease pathways and drug responses in a more meaningful liver disease pre-clinical context. For more information please visit www.liver.barcelona